8,596
Total Claims
$1.6M
Drug Cost
1,115
Beneficiaries
$1,435
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-6%
Cost per patient vs peers
$1,435 vs $1,524 avg
+41%
Brand preference vs peers
19.3% vs 13.7% avg
Brand vs Generic
81% generic
Brand: 1,659 claims · $1.3M
Generic: 6,937 claims · $251K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 537 | $447K |
| Dapagliflozin Propanediol | 354 | $263K |
| Sacubitril/Valsartan | 214 | $238K |
| Empagliflozin | 115 | $100K |
| Rivaroxaban | 113 | $93K |
| Dronedarone Hcl | 67 | $80K |
| Ranolazine | 406 | $56K |
| Ticagrelor | 46 | $28K |
| Prasugrel Hcl | 66 | $15K |
| Metoprolol Succinate | 627 | $14K |
| Flecainide Acetate | 137 | $11K |
| Labetalol Hcl | 150 | $8,291 |
| Atorvastatin Calcium | 365 | $7,720 |
| Pravastatin Sodium | 203 | $7,535 |
| Bumetanide | 233 | $7,262 |
Prescribing Profile
65
Unique Drugs
$1.1M
Patient Profile
74
Avg Age
61%
Female
1.87
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data